Protai Overview
Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered. The company is building machine learning models combining deep proteomics to identify up to 1 million proteoforms, including post-translational modifications, protein-protein interactions, quantifications, and different structural populations of proteins.
Cumulative Funding Raised Over Time ($)
$8.0MJan 2022
$20.0MMar 2023
Latest News
growth-positive
/PRNewswire/ -- Protai, www.protai.bio, a structural proteomics and AI-driven biotech, announced its participation in four major scientific conferences this...
Protai, a structural proteomics and AI-driven biotech company, is making significant strides in the field of drug discovery by integrating AI with structural proteomics. The company is participating in four major scientific conferences in October, showcasing its pioneering advances in targeted protein degradation and TNFα signaling complex modeling. Protais AIMS™ platform bridges AI and structural proteomics to reveal hidden druggable pockets in complex proteins, enabling the design of small-molecule therapeutics. The company is expanding into the Immunology & Inflammation space, aiming to transform the discovery of PPI inhibitors and induced proximity therapeutics. Protais pipeline targets oncology and immunology, addressing significant unmet medical needs.
growth-positive
/PRNewswire/ -- Protai, a structural-proteomics & AI driven biotech, has announced the addition of three leading scientists to its advisory board. This move is...
Protai, a biotech company specializing in structural proteomics and AI-driven drug discovery, has announced the addition of three prominent scientists to its advisory board. This strategic move aims to accelerate Protais drug discovery programs and expand its focus into immunology and inflammation diseases. The new advisors, Dr. Philip Jones, Dr. Ian Churcher, and Dr. Annalisa DAndrea, bring extensive expertise in drug discovery, targeted protein degradation, and immunology, respectively. Their combined knowledge is expected to enhance Protais capabilities in developing effective and safe drugs. Protais CEO, Eran Seger, expressed confidence that the new advisory board members will significantly contribute to the companys growth and innovation in the biotech field.
growth-positive
Protai adds $12 million to Seed round as it aims to build oncology drug discovery pipeline | CTech
Israeli startup Protai has raised an additional $12 million in its Seed round, bringing the total amount to $20 million. Protai has developed a proteomics and AI-powered drug discovery platform that maps the course of a disease on the protein level. The platform aims to predict patient responses to drugs and discover novel drug targets. The funding will support Protais mission to enhance the drug development pathway. The company has opened laboratories, recruited a drug discovery team, and established collaborations with leading hospitals. Protai focuses on gyno-oncology and lung cancer indications.
Investment
growth-positive
How Protai's AI-powered platform is improving drug discovery
Protai, a Tel-Aviv-based AI-powered drug discovery startup, has emerged from stealth mode with $8 million in seed funding. The company uses proteomics and an AI-based platform to reshape the drug discovery and development process. Protais technology maps the course of a disease on the protein level, improving the capacity to observe cellular function and enhancing the cost-effectiveness of new drug discovery. The funding, co-led by Grove Ventures and Pitango Venture Capital, will be used to further develop Protais platform, accelerate its discovery programs, and enhance its partnerships with pharmaceutical companies.
InvestmentExpand
growth-positive
Protai Raises $8 Million Seed Round to Provide a Proteomics-based Platform for Faster and More Accurate Drug Discovery
Protai, an AI-powered drug discovery startup, has emerged from stealth with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech. The funding will be used to further develop Protais platform, accelerate its discovery programs, and enhance its partnerships with pharmaceutical companies. Protai has built an end-to-end AI-based platform that maps diseases on the protein level, improving the way new drugs are discovered. The company has created a large proteomic database and aims to revolutionize proteomics-based drug discovery. Protai is backed by Grove Ventures and Pitango HealthTech.
InvestmentPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $20M |
| Last funding | $12M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 2 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | www.protai.bio/ |
| Careers | Careers page |
Locations
Tel Aviv, Israel
Photos & Videos
No files yet
Protai Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
Artificial IntelligenceMachine LearningPlatforms & InterfacesSoftwareTags (11)
data-analyticsbiotechnologydecision-supportdisease-managementproteinsdigital-healthcareartificial-intelligencedrug-discoverypersonalizationsoftware-platformpharma-companiesProtai Financials
$20M
Total funding
Undisclosed
Capital raised
$12M
Last funding
Seed
Funding stage
2
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$8.0MJan 2022
$20.0MMar 2023
Private Equity Funding
Seed
Mar 2023
$12M
Pitango HealthTech, Grove Ventures
Seed
Jan 2022
$8M
Grove Ventures (Lead)
,
Pitango HealthTech
Protai Lifecycle
Cumulative Funding Raised Over Time
$8.0MJan 2022
$20.0MMar 2023
All Events
Seed
Mar 2023
$12M
Pitango HealthTech, Grove Ventures
Seed
Jan 2022
$8M
Grove Ventures (Lead)
,
Pitango HealthTech
Protai News
5 articles
growth-positive
/PRNewswire/ -- Protai, www.protai.bio, a structural proteomics and AI-driven biotech, announced its participation in four major scientific conferences this...
Protai, a structural proteomics and AI-driven biotech company, is making significant strides in the field of drug discovery by integrating AI with structural proteomics. The company is participating in four major scientific conferences in October, showcasing its pioneering advances in targeted protein degradation and TNFα signaling complex modeling. Protais AIMS™ platform bridges AI and structural proteomics to reveal hidden druggable pockets in complex proteins, enabling the design of small-molecule therapeutics. The company is expanding into the Immunology & Inflammation space, aiming to transform the discovery of PPI inhibitors and induced proximity therapeutics. Protais pipeline targets oncology and immunology, addressing significant unmet medical needs.
growth-positive
/PRNewswire/ -- Protai, a structural-proteomics & AI driven biotech, has announced the addition of three leading scientists to its advisory board. This move is...
Protai, a biotech company specializing in structural proteomics and AI-driven drug discovery, has announced the addition of three prominent scientists to its advisory board. This strategic move aims to accelerate Protais drug discovery programs and expand its focus into immunology and inflammation diseases. The new advisors, Dr. Philip Jones, Dr. Ian Churcher, and Dr. Annalisa DAndrea, bring extensive expertise in drug discovery, targeted protein degradation, and immunology, respectively. Their combined knowledge is expected to enhance Protais capabilities in developing effective and safe drugs. Protais CEO, Eran Seger, expressed confidence that the new advisory board members will significantly contribute to the companys growth and innovation in the biotech field.
growth-positive
Protai adds $12 million to Seed round as it aims to build oncology drug discovery pipeline | CTech
Israeli startup Protai has raised an additional $12 million in its Seed round, bringing the total amount to $20 million. Protai has developed a proteomics and AI-powered drug discovery platform that maps the course of a disease on the protein level. The platform aims to predict patient responses to drugs and discover novel drug targets. The funding will support Protais mission to enhance the drug development pathway. The company has opened laboratories, recruited a drug discovery team, and established collaborations with leading hospitals. Protai focuses on gyno-oncology and lung cancer indications.
Investment
growth-positive
How Protai's AI-powered platform is improving drug discovery
Protai, a Tel-Aviv-based AI-powered drug discovery startup, has emerged from stealth mode with $8 million in seed funding. The company uses proteomics and an AI-based platform to reshape the drug discovery and development process. Protais technology maps the course of a disease on the protein level, improving the capacity to observe cellular function and enhancing the cost-effectiveness of new drug discovery. The funding, co-led by Grove Ventures and Pitango Venture Capital, will be used to further develop Protais platform, accelerate its discovery programs, and enhance its partnerships with pharmaceutical companies.
InvestmentExpand
growth-positive
Protai Raises $8 Million Seed Round to Provide a Proteomics-based Platform for Faster and More Accurate Drug Discovery
Protai, an AI-powered drug discovery startup, has emerged from stealth with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech. The funding will be used to further develop Protais platform, accelerate its discovery programs, and enhance its partnerships with pharmaceutical companies. Protai has built an end-to-end AI-based platform that maps diseases on the protein level, improving the way new drugs are discovered. The company has created a large proteomic database and aims to revolutionize proteomics-based drug discovery. Protai is backed by Grove Ventures and Pitango HealthTech.
InvestmentPartners
Protai Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 25 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Protai Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 516427895 |
| Creator | Santiago Kesel |
| Creator email | santi.kesel@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-06-08T00:00:00.000Z |
| Created | 2021-12-15T00:00:00.000Z |